is a nuclear medicine physician with two decades of clinical experience, both
in the Netherlands and in Canada. His areas of expertise are radioisotope treatments
of cancer and the investigation of novel PET tracers in oncology. He has served
on several expert panels, in particular in the fields of radioimmunotherapy of
lymphoma and the treatment of neuroendocrine tumours.
Postema’s research focus has been on phase I, II, and III trials of novel
radiopharmaceuticals in oncology, either for therapeutic or diagnostic purposes.
He has written multiple scientific papers and has held numerous presentations.
He was an Assistant Professor at the Department of Oncology of the University
of Alberta. He has served on the editorial board of a renowned medical journal
in his field and currently continues to do so.
consultant is a certified physician who has served on Internal Review Boards
both in Canada and the Netherlands. He has also chaired ethics boards in both countries.
Not only has he reviewed numerous research protocols, he also has hands-on
experience in the preregistration phase of new radiopharmaceuticals; having
submitted necessary documentation to national and federal agencies. Dr. Postema
is also formally certified to design preclinical studies. With respect to radiation
safety, he is qualified in several jurisdictions.
Certificate in Health Services Management, University of Plymouth
Katholieke Universiteit Nijmegen
as a nuclear medicine physician
degree, Erasmus Universiteit Rotterdam